Asher A. Chanan-Khan, MBBS, MD

Department of Cancer Biology, Mayo Clinic and Mayo Clinic Cancer Center at St. Vincent’s Medical Center Riverside

N/A

Poster(s):

• 1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

• 1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies